Clinical trials: Obesity, Overweight
Healthy
A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood
This study is open to women with overweight or obesity who are otherwise healthy. Women with a body mass index (BMI) from 27 to 40 kg/m2 can participate.
- Trial name
- NCT05896384
- Testing
- BI 456906, Microgynon®
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Obesity
Cities for Better Health Childhood Obesity Prevention Initiative
This research project is part of the 'Cities for Better Health Childhood Obesity Prevention Initiative' (CBH COPI). The objective of the CBH COPI initiative is to develop, implement, and evaluate the effectiveness of a package of…
- Trial name
- CBH COPI (NCT06855563)
- Testing
- Community-based intervention packages
- Where
- 6 sites in Australia, Brazil and 4 more
- Volunteers
- 36,000 people
- Sponsor
- Novo Nordisk A/S
Type II Diabetes
Safety and Efficacy Study of EndoBarrier in Subjects With Type II Diabetes and Obesity
The purpose of this study is to evaluate the safety and efficacy of a second generation EndoBarrier Liner compared to a study diet to treat Subjects with Type 2 Diabetes.
- Trial name
- NCT00985114
- Testing
- EndoBarrier, Diet + Lifestyle Counseling
- Where
- 3 sites in Netherlands
- Volunteers
- 77 people
- Sponsor
- Morphic Medical Inc.
Obesity & Overweight
Polydextrose Functional Gummies for Weight Management in Adults With Overweight or Obesity
Overweight and obesity are common conditions that increase the risk of metabolic and cardiovascular diseases. Polydextrose is a type of dietary fiber that may help increase feelings of fullness by influencing natural hormones…
- Trial name
- DEXTRO-PESO (NCT07758387)
- Testing
- Polydextrose Gummies
- Where
- Spain
- Volunteers
- 96 people
- Sponsor
- Nutris We Care About You S.L.
Atherosclerotic Cardiovascular Disease, Overweight
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.
- Conditions
- Atherosclerotic Cardiovascular Disease, Overweight, Obesity
- Trial name
- MARITIME-CV (NCT07037433)
- Testing
- Maridebart Cafraglutide
- Where
- 783 sites in United States, Argentina and 34 more
- Volunteers
- 12,800 people
- Sponsor
- Amgen
Sleep Apnea, Obstructive
A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of IBI362 in subjects with moderate-to-severe obstructive sleep apnea (OSA) and a body mass index…
- Conditions
- Sleep Apnea, Obstructive, Obesity
- Trial name
- NCT06931028
- Testing
- IBI362
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Obesity/Overweight
Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver Function
This study adopts a multicenter, single-dose, open-label, and parallel design, which is aimed at assessing the PK and safety profiles of GZR18 Injection in subjects with normal liver function and those with mild, moderate or…
- Trial name
- NCT07144098
- Testing
- GZR18 injection
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Gan & Lee Pharmaceuticals.
Overweight and Obesity
Web-based Weight Loss Intervention
Excess weight is a major risk factor underlying leading causes of death globally, including cardiovascular disease, type 2 diabetes, and some cancers.
- Trial name
- NCT03400696
- Testing
- Lower carbohydrate diet, Higher fiber diet, Physical activity focused
- Where
- 2 sites in United States
- Volunteers
- 63,656 people, healthy volunteers welcome
- Sponsor
- 23andMe, Inc.
Healthy Subjects
A Study To Assess The Safety, Tolerability, And Pharmacokinetics (PK) Of Multiple Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects
This will be an investigator- and subject-blinded (sponsor open), randomized, placebo controlled, sequential, ascending, multiple oral dose study, with 5 planned cohorts (optional sixth and seventh cohorts).
- Trial name
- NCT03230383
- Testing
- PF-06865571
- Where
- 2 sites in United States, Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity
Vestibular Stimulation to Trigger Adipose Loss (VeSTAL) Clinical Trial
A randomized, double blind sham controlled clinical trial to evaluate the efficacy of vestibular nerve stimulation (VeNS), combined with a lifestyle modification program, compared to a sham control and a lifestyle modification…
- Trial name
- VeSTAL (NCT03640286)
- Testing
- VeSTAL
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- Neurovalens Ltd.
Obesity, Type 2 Diabetes Mellitus
Procedure for Duodenal-Ileal Diversion With a Sleeve Gastrectomy for Patients With Obesity and Type 2 Diabetes Mellitus
Study will monitor weight loss and metabolic indicators for subjects in multi-center, single arm trial.
- Trial name
- NCT04627103
- Testing
- Self Forming Magnetic (SFM) Anastomosis System
- Where
- 2 sites in Canada
- Volunteers
- 18 people
- Sponsor
- GI Windows, Inc.
Diabetes Mellitus, Diabetes Mellitus, Type 2
Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects
This study is designed to assess the safety, tolerability and pharmacokinetics of multiple oral 200-mg doses of Pf-05175157 administered twice daily for 14 days in healthy overweight and obese subjects.
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
- Trial name
- NCT01757756
- Testing
- Pf-05175157, midazolam
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity, Overweight
A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
A study to assess the effect of CT-868 in lowering glycated hemoglobin A1c (HbA1c) in overweight and obese participants with inadequately controlled Type 2 diabetes mellitus (T2DM).
- Conditions
- Obesity, Overweight, Type 2 Diabetes Mellitus
- Trial name
- NCT05110846
- Testing
- CT-868
- Where
- 5 sites in Mexico
- Volunteers
- 103 people
- Sponsor
- Carmot Therapeutics, Inc.
Obesity, Overweight
A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight
The primary objective is to evaluate the safety and tolerability of VRB-103 tablets administered as monotherapy or VRB-103 tablets administered in combination with oral ecnoglutide tablets (VRB-101 tablets) in a single-dose…
- Trial name
- NCT07628127
- Testing
- VRB-103, VRB-101
- Where
- 3 sites in Australia
- Volunteers
- 332 people, healthy volunteers welcome
- Sponsor
- Verdiva Bio Dev Limited
Impaired Glucose Tolerance, Abdominal Obesity
Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity.
The purpose of this study is to evaluate the efficacy of GFT505 80mg compared with placebo in improving Oral Glucose Tolerance Test (OGTT), in patients with impaired glucose tolerance and abdominal obesity, and to assess the…
- Trial name
- NCT01275469
- Testing
- GFT505 80mg
- Where
- 20 sites in France
- Volunteers
- 47 people
- Sponsor
- Genfit
Obesity or Overweight
A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight
The main purpose of this study is to evaluate the safety and efficacy of the co-administration of petrelintide and enicepatide compared with placebo, petrelintide monotherapy, and enicepatide monotherapy in participants with…
- Trial name
- ZYNERGY (NCT07589686)
- Testing
- Petrelintide, Enicepatide
- Volunteers
- 486 people
- Sponsor
- Hoffmann-La Roche
Obesity
Safety Study of LLF580 in Obese Volunteers
The purpose of the study is to evaluate the safety and tolerability of multiple doses of LLF580 administered subcutaneously over 3 months in obese subjects.
- Trial name
- NCT03466203
- Testing
- LLF580
- Where
- 7 sites in United States
- Volunteers
- 61 people
- Sponsor
- Novartis Pharmaceuticals
Obesity, HIV Infections
A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity
This is a multicenter, randomized, placebo-controlled, double-blind, Phase 2 study. Patients will be treated for a total of 12 weeks. There will be a 6 week follow-up period after the treatment period ends.
- Trial name
- NCT00267527
- Testing
- CJC 1295
- Volunteers
- 120 people
- Sponsor
- ConjuChem
Obstructive Sleep Apnea, Obesity
UBT251 Injection Phase Ⅲ Study (OSA-NPAP)
The objective of this clinical trial is to evaluate the efficacy of investigational drug UBT251 in the treatment of moderate-to-severe obstructive sleep apnea (OSA) with obesity, as well as to assess its safety.
- Trial name
- UNISHAPE-OSA-1 (NCT07767942)
- Testing
- UBT251
- Volunteers
- 150 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Obstructive Sleep Apnea, Obesity
Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea
The purpose of this study is to evaluate the effect and safety of tirzepatide in participants with moderate to severe obstructive sleep apnea and obesity who are both unwilling or unable to use Positive Airway Pressure (PAP)…
- Trial name
- SURMOUNT-OSA (NCT05412004)
- Testing
- Tirzepatide
- Where
- 58 sites in United States, Australia and 8 more
- Volunteers
- 469 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.